Clinical benefit response of concurrent chemoradiotherapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer

Takuji Okusaka(National Cancer Centre Japan), Hiroshi Ikeda, Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Masayoshi Yoshimori(Tokyo National Hospital), Hiroshi Ishii(Chiba Cancer Center), Hidekazu Nakasuka(Tokyo National Hospital), Kouichi Tokuuye(National Cancer Centre Japan), Hiroyasu Nagahama(Kyushu University), Shuichi Okada(Tokyo National Hospital), Yoshikazu Kagami(Tokyo National Hospital)
International Journal of Clinical Oncology
April 1, 1998
10.1007/bf02492854
Cited by 0

Related Papers

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632